AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riggs, M. W.
Right arrow Articles by Perryman, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riggs, M. W.
Right arrow Articles by Perryman, L. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 275-282, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.275-282.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Efficacy of Monoclonal Antibodies against Defined Antigens for Passive Immunotherapy of Chronic Gastrointestinal Cryptosporidiosis

Michael W. Riggs,1* Deborah A. Schaefer,1 Sushila J. Kapil,2 Lise Barley-Maloney,2 and Lance E. Perryman2

Department of Veterinary Science and Microbiology, University of Arizona, Tucson, Arizona, 85721,1 Department of Microbiology, Pathology, and Parasitology, North Carolina State University, Raleigh, North Carolina 276062

Received 7 May 2001/ Returned for modification 14 July 2001/ Accepted 13 October 2001

Cryptosporidium parvum is an important cause of diarrhea in humans and calves and can persistently infect immunocompromised hosts. Presently, there are no consistently effective parasite-specific drugs for cryptosporidiosis. We hypothesized that neutralizing monoclonal antibodies (MAbs) targeting the apical complex and surface antigens CSL, GP25-200, and P23 could passively immunize against cryptosporidiosis. We recently reported that a formulation of MAbs 3E2 (anti-CSL), 3H2 (anti-GP25-200), and 1E10 (anti-P23) provided significant additive prophylactic efficacy over that of the individual MAbs in neonatal ICR mice. In the present study, these MAbs were evaluated for therapeutic efficacy against persistent infection in adult gamma interferon-depleted SCID mice. 3E2 demonstrated the most significant and consistent therapeutic effect, reducing intestinal infection in two experiments. In one experiment, 3E2 plus 3H2 and 3E2 plus 3H2 plus 1E10 also significantly reduced infection; however, no significant increase in efficacy over 3E2 alone was apparent. The results indicate that anti-CSL MAb 3E2 has highly significant efficacy in reducing, but not eliminating, persistent C. parvum infection.

* Corresponding author. Mailing address: Department of Veterinary Science and Microbiology, Veterinary Science and Microbiology Building, Room 202, University of Arizona, Tucson, AZ 85721. Phone: (520) 621-2355. Fax: (520) 621-6366. E-mail: mriggs{at}u.arizona.edu.

Antimicrobial Agents and Chemotherapy, February 2002, p. 275-282, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.275-282.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.